Early Changes in [(18)F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts

We investigated the potential use of [(18)F]FDG PET as a response biomarker for PI3K pathway targeting therapies in two HER-2-overexpressing cancer models. Methods. CD-1 nude mice were inoculated with HER-2-overexpressing JIMT1 (trastuzumab-resistant) or SKOV3 (trastuzumab-sensitive) human cancer ce...

Descripción completa

Detalles Bibliográficos
Autores principales: Dockx, Yanina, Vangestel, Christel, Van den Wyngaert, Tim, Huizing, Manon, De Bruycker, Sven, Pauwels, Patrick, Staelens, Steven, Stroobants, Sigrid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169268/
https://www.ncbi.nlm.nih.gov/pubmed/34113218
http://dx.doi.org/10.1155/2021/5594514

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8169268/
https://www.ncbi.nlm.nih.gov/pubmed/34113218
http://dx.doi.org/10.1155/2021/5594514

Ejemplares similares